FDA to Continue to Refuse Imports from Jamaican Drug Company
The Food and Drug Administration sent a warning letter to P.A. Benjamin Manufacturing, a drug company based in Jamaica, detailing violations of current good manufacturing practice regulations, as well as unapproved new drug and misbranding violations. Specific problems included labeling…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
violations and use of active ingredients that do not comply with requirements for cold and cough medicines for over-the-counter use. FDA said it may continue to refuse admission of drugs manufactured at P.A. Benjamin’s Kingston facility as a result.